Company news
Gossamer Bio, Inc. (NASDAQ:GOSS) news
Gossamer Bio, Inc. news releases on 6ix. Latest, May 18, 2023: Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023…
Press releases — page 2
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
May 17, 2023
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
March 16, 2023
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
December 5, 2022
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
November 2, 2022
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Gossamer Bio Announces $120 Million Private Placement Financing
July 12, 2022
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
June 8, 2022
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
May 9, 2022
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
April 24, 2022
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
March 2, 2022
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
February 27, 2022
Onxeo Continues to Strengthen its Board of Directors
November 22, 2021
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 7, 2021
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
November 1, 2021
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
October 10, 2021
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
October 6, 2021
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
September 20, 2021
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 8, 2021
Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
August 1, 2021
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation
July 6, 2021
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
June 20, 2021
Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors
June 13, 2021
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
April 19, 2021
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
April 15, 2021
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
February 24, 2021
Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021
February 18, 2021
Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
February 3, 2021
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
December 10, 2020
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
December 6, 2020
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
November 15, 2020
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 9, 2020
Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020
November 5, 2020
Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting
November 5, 2020
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
October 12, 2020
Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates
October 11, 2020
Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020
October 8, 2020
Gossamer Bio Announces Participation in Upcoming Investor Conferences
September 9, 2020
Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020
September 6, 2020
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
August 31, 2020
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020
Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference
August 4, 2020
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program
May 28, 2020
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
May 17, 2020
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020
Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020
May 7, 2020
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 23, 2020
Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference
February 17, 2020
Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation
February 12, 2020